MDxHealth price target lowered to $6 from $8 at BTIG
The Fly

MDxHealth price target lowered to $6 from $8 at BTIG

BTIG analyst Mark Massaro lowered the firm’s price target on MDxHealth (MDXH) to $6 from $8 and keeps a Buy rating on the shares. The company is an attractive small-cap growth and value stock and a one-stop-shop in personalized prostate diagnostics testing, though the firm is updating its model to bake in some dilution from MDxHealth’s recent $40M public offering, the analyst tells investors in a research note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App